These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36592497)

  • 1. The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer.
    Kicken MP; Kilinc HD; Cramer-van der Welle CM; Houterman S; van den Borne BEEM; Smit AAJ; van de Garde EMW; Deenen MJ;
    Cancer Treat Res Commun; 2023; 34():100676. PubMed ID: 36592497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity and prognosis in overweight and obese women with lung cancer receiving carboplatin-paclitaxel doublet chemotherapy.
    Kashiwabara K; Yamane H; Tanaka H
    Cancer Invest; 2013 May; 31(4):251-7. PubMed ID: 23607633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity and effectiveness of carboplatin in obese or overweight patients.
    Grueso Cuesta C; Poquet Jornet JE; Gasent Blesa JM; Valdivia Perez A; Carrera Hueso FJ; Moreno Royo L
    J Oncol Pharm Pract; 2019 Sep; 25(6):1328-1335. PubMed ID: 30086680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
    Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
    Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of body mass index on survival of patients with stage I non-small cell lung cancer.
    Xie HJ; Zhang X; Wei ZQ; Long H; Rong TH; Su XD
    Chin J Cancer; 2017 Jan; 36(1):7. PubMed ID: 28069048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of body mass index on survival and serious adverse events in advanced non-small cell lung cancer treated with bevacizumab: a meta-analysis of randomized clinical trials.
    Shukla S; Babcock Z; Pizzi L; Brunetti L
    Curr Med Res Opin; 2021 May; 37(5):811-817. PubMed ID: 33685311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.
    Kaag D
    Lung Cancer; 2013 Jan; 79(1):54-8. PubMed ID: 23131495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials.
    Li LX; Socinski MA; Kichenadasse G; Karapetis CS; Shahnam A; McKinnon RA; Rowland A; Hopkins AM; Sorich MJ
    BMC Cancer; 2024 Mar; 24(1):379. PubMed ID: 38528478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Body Mass Index With Outcomes Among Patients With Head and Neck Cancer Treated With Chemoradiotherapy.
    Ma SJ; Khan M; Chatterjee U; Santhosh S; Hashmi M; Gill J; Yu B; Iovoli A; Farrugia M; Wooten K; Gupta V; McSpadden R; Yu H; Kuriakose MA; Markiewicz MR; Al-Afif A; Hicks WL; Seshadri M; Ray AD; Repasky E; Singh AK
    JAMA Netw Open; 2023 Jun; 6(6):e2320513. PubMed ID: 37368400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.
    Barrett SV; Paul J; Hay A; Vasey PA; Kaye SB; Glasspool RM;
    Ann Oncol; 2008 May; 19(5):898-902. PubMed ID: 18272913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer.
    Hatta T; Hase T; Hara T; Kimura T; Kojima E; Abe T; Horio Y; Goto Y; Ozawa N; Yogo N; Shibata H; Shimokata T; Oguri T; Yamamoto M; Yanagisawa K; Ando M; Ando Y; Kondo M; Ishii M; Hasegawa Y
    Cancer Med; 2023 Aug; 12(15):15955-15969. PubMed ID: 37351560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study.
    Li W; Shen LJ; Chen T; Sun XQ; Zhang Y; Wu M; Shu WH; Chen C; Pan CC; Xia YF; Wu PH
    Chin J Cancer; 2016 Aug; 35(1):75. PubMed ID: 27507261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
    Cortellini A; Ricciuti B; Tiseo M; Bria E; Banna GL; Aerts JG; Barbieri F; Giusti R; Cortinovis DL; Migliorino MR; Catino A; Passiglia F; Torniai M; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Rastelli F; Chiari R; Rocco D; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Grossi F; Filetti M; Pizzutilo P; Russano M; Citarella F; Cantini L; Targato G; Nigro O; Ferrara MG; Buti S; Scodes S; Landi L; Guaitoli G; Della Gravara L; Tabbò F; Ricciardi S; De Toma A; Friedlaender A; Petrelli F; Addeo A; Porzio G; Ficorella C
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes.
    Harris BDW; Phan V; Perera V; Szyc A; Galettis P; Martin JH; Walpole E; McLachlan AJ; Clarke SJ; Reuter SE; Charles KA
    Clin Pharmacokinet; 2020 Aug; 59(8):1013-1026. PubMed ID: 32034726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients.
    de Jong C; Chargi N; Herder GJM; van Haarlem SWA; van der Meer F; van Lindert ASR; Ten Heuvel A; Brouwer J; de Jong PA; Devriese LA; Huitema ADR; Egberts TCG; de Bree R; Deneer VHM
    J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1554-1564. PubMed ID: 35301821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
    Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
    J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.